Science Explorer Back to mapMap
Discussion
Company · Burlingame · United States

Innoviva (United States)

investor.inva.comROR OpenAlex
Research works
12
▲ 6900% vs 2018-21
Citations
69
5.8 per fractional work
Top-10% rate
15.7%
all institutions 10.0%
Open access
90%
world 40%
International
29%
world 18%
Innoviva (United States)

Not ranked overall: Innoviva (United States) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Innoviva (United States) work in?

In all years, 42% of research at Innoviva (United States) is in Life Sciences, 37% in Health Sciences. Its largest fields are Medicine (37%), Immunology and Microbiology (21%), Biochemistry, Genetics and Molecular Biology (18%). It does 1.7× the world's share of Life Sciences.

Life Sciences: 5 fractional works · 42.1% of its workImmunology and Microbiology: 2 fractional works · 20.5% of its workApplied Microbiology and Biotechnology: 1 fractional works · 11.4% of its workMicrobiology: 1 fractional works · 9.1% of its workBiochemistry, Genetics and Molecular Biology: 2 fractional works · 18.3% of its workMolecular Medicine: 2 fractional works · 14.9% of its workMolecular Biology: 0 fractional works · 2.8% of its workEndocrinology: 0 fractional works · 0.7% of its workAgricultural and Biological Sciences: 0 fractional works · 2.3% of its workPlant Science: 0 fractional works · 1.7% of its workGeneral Agricultural and Biological Sciences: 0 fractional works · 0.6% of its workSmaller subfields together: 0 fractional works · 0.1% of its workPharmacology, Toxicology and Pharmaceutics: 0 fractional works · 0.9% of its workToxicology: 0 fractional works · 0.9% of its workHealth Sciences: 4 fractional works · 37.0% of its workMedicine: 4 fractional works · 36.8% of its workPharmacology: 2 fractional works · 14.4% of its workInfectious Diseases: 1 fractional works · 5.1% of its workPediatrics, Perinatology and Child Health: 1 fractional works · 4.9% of its workEpidemiology: 0 fractional works · 4.2% of its workCardiology and Cardiovascular Medicine: 0 fractional works · 2.1% of its workGeriatrics and Gerontology: 0 fractional works · 1.5% of its workNephrology: 0 fractional works · 1.1% of its workDermatology: 0 fractional works · 0.7% of its workOncology: 0 fractional works · 0.7% of its workHematology: 0 fractional works · 0.5% of its workSurgery: 0 fractional works · 0.5% of its workCritical Care and Intensive Care Medicine: 0 fractional works · 0.4% of its workPulmonary and Respiratory Medicine: 0 fractional works · 0.3% of its workEmergency Medicine: 0 fractional works · 0.3% of its workSmaller subfields together: 0 fractional works · 0.3% of its workHealth Professions: 0 fractional works · 0.2% of its workSocial Sciences: 2 fractional works · 13.6% of its workDecision Sciences: 1 fractional works · 8.8% of its workManagement Science and Operations Research: 1 fractional works · 8.4% of its workStatistics, Probability and Uncertainty: 0 fractional works · 0.4% of its workSocial Sciences: 0 fractional works · 3.3% of its workPolitical Science and International Relations: 0 fractional works · 1.4% of its workSafety Research: 0 fractional works · 1.4% of its workEducation: 0 fractional works · 0.6% of its workEconomics, Econometrics and Finance: 0 fractional works · 1.4% of its workEconomics and Econometrics: 0 fractional works · 1.4% of its workPhysical Sciences: 1 fractional works · 7.4% of its workEnvironmental Science: 0 fractional works · 2.8% of its workPollution: 0 fractional works · 2.8% of its workPhysics and Astronomy: 0 fractional works · 1.9% of its workNuclear and High Energy Physics: 0 fractional works · 0.8% of its workAstronomy and Astrophysics: 0 fractional works · 0.7% of its workRadiation: 0 fractional works · 0.4% of its workComputer Science: 0 fractional works · 1.5% of its workComputer Networks and Communications: 0 fractional works · 0.9% of its workInformation Systems: 0 fractional works · 0.6% of its workMathematics: 0 fractional works · 0.7% of its workStatistics and Probability: 0 fractional works · 0.7% of its workEngineering: 0 fractional works · 0.5% of its workComputational Mechanics: 0 fractional works · 0.4% of its workSmaller subfields together: 0 fractional works · 0.1% of its workALL ITS WORKInnoviva (UnitedStates)12fractional works, all years
Life Sciences42%Physical Sciences7%Health Sciences37%Social Sciences14%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 14 fields, with their numbers
    1. Immunology and Microbiology220.5%
    2. Biochemistry, Genetics and Molecular Biology218.3%
    3. Agricultural and Biological Sciences02.3%
    4. Pharmacology, Toxicology and Pharmaceutics00.9%
    1. Medicine436.8%
    2. Health Professions00.2%
    1. Decision Sciences18.8%
    2. Social Sciences03.3%
    3. Economics, Econometrics and Finance01.4%
    1. Environmental Science02.8%
    2. Physics and Astronomy01.9%
    3. Computer Science01.5%
    4. Mathematics00.7%
    5. Engineering00.5%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Agricultural and Biological Sciences: 0.03× its world share, 0 worksAgricultural and Bio…Biochemistry, Genetics and Molecular Biology: 3.60× its world share, 2 worksBiochemistry, Geneti…Immunology and Microbiology: 21.31× its world share, 2 worksImmunology and Micro…Pharmacology, Toxicology and Pharmaceutics: 2.76× its world share, 0 worksPharmacology, Toxico…Computer Science: 0.12× its world share, 0 worksComputer ScienceEngineering: 0.04× its world share, 0 worksEngineeringEnvironmental Science: 0.59× its world share, 0 worksEnvironmental ScienceMathematics: 0.62× its world share, 0 worksMathematicsPhysics and Astronomy: 0.41× its world share, 0 worksPhysics and AstronomyHealth Professions: 0.06× its world share, 0 worksHealth ProfessionsMedicine: 2.00× its world share, 4 worksMedicineDecision Sciences: 9.48× its world share, 1 worksDecision SciencesEconomics, Econometrics and Finance: 0.68× its world share, 0 worksEconomics, Econometr…Social Sciences: 0.23× its world share, 0 worksSocial Sciences1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 21.3×. Every wedge is a field page.

All 14 fields, with their numbers
  1. Immunology and Microbiology21.31×2 works
  2. Decision Sciences9.48×1 works
  3. Biochemistry, Genetics and Molecular Biology3.60×2 works
  4. Pharmacology, Toxicology and Pharmaceutics2.76×0 works
  5. Medicine2.00×4 works
  6. Economics, Econometrics and Finance0.68×0 works
  7. Mathematics0.62×0 works
  8. Environmental Science0.59×0 works
  9. Physics and Astronomy0.41×0 works
  10. Social Sciences0.23×0 works
  11. Computer Science0.12×0 works
  12. Health Professions0.06×0 works
  13. Engineering0.04×0 works
  14. Agricultural and Biological Sciences0.03×0 works

Who are the top researchers at Innoviva (United States)?

Ranked on the quality score, Tony Hodges lead among researchers whose main affiliation is Innoviva (United States).

  1. 1 Tony Hodges United States · #1,175,483 worldwide 904 citations · 57 works
All ranked researchers at Innoviva (United States)

What are the most cited papers from Innoviva (United States)?

The most cited paper from Innoviva (United States) is "Antimicrobial susceptibility of Treponema pallidum subspecies pallidum: an in-vitro study" (Lauren C. Tantalo, Nicole A. P. Lieberman, Clara Pérez‐Mañá et al., 2023), with 60 citations. Next come "Molecular drivers of resistance to sulbactam-durlobactam in contemporary clinical isolates ofAcinetobacter baumannii" (51) and "Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial" (45).

Most cited papers
#PaperReleasedCitations
1 Antimicrobial susceptibility of Treponema pallidum subspecies pallidum: an in-vitro study Lauren C. Tantalo, Nicole A. P. Lieberman, Clara Pérez‐Mañá et al. · The Lancet Microbe Open access 9 Oct 2023 60
2 Molecular drivers of resistance to sulbactam-durlobactam in contemporary clinical isolates ofAcinetobacter baumannii Samir H. Moussa, Adam B. Shapiro, Sarah M. McLeod et al. · Antimicrobial Agents and Chemotherapy Open access 16 Oct 2023 51
3 Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial Alison Luckey et al. · The Lancet Open access 11 Dec 2025 45
4 ACE inhibitors and angiotensin receptor blockers differentially alter the response to angiotensin II treatment in vasodilatory shock Daniel E. Leisman, Damian R. Handisides, Laurence W. Busse et al. · Critical Care Open access 18 Apr 2024 36
5 Angiotensin II treatment is associated with improved oxygenation in ARDS patients with refractory vasodilatory shock Daniel E. Leisman, Damian R. Handisides, Lakhmir S. Chawla et al. · Annals of Intensive Care Open access 2023 23
All 33 most cited papers, with filters and sorting

Which research topics does Innoviva (United States) publish most on?

By volume in 2022-now: Antibiotic Resistance in Bacteria, Antibiotics Pharmacokinetics and Efficacy, Antibiotic Use and Resistance and Complex Systems and Decision Making.

Antibiotic Resistance in…2Antibiotic Resistance in Bacteria: 2 fractional worksAntibiotics Pharmacokinetics and Efficacy: 2 fractional worksAntibiotic Use and Resistance: 1 fractional worksComplex Systems and Decision Making: 1 fractional worksReproductive tract infections research: 1 fractional worksAntimicrobial Resistance…1Antimicrobial Resistance in Staphylococcus: 1 fractional worksPharmaceutical studies and practices: 0 fractional worksBacterial Infections and Vaccines: 0 fractional worksBacterial biofilms and quorum sensing: 0 fractional worksPharmaceutical and Antibiotic Environmental Impacts: 0 fractional works
Molecular MedicinePharmacologyApplied Microbiology and BiotechnologyManagement Science and Operations Research5 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Antibiotic Resistance in Bacteria Molecular Medicine 2 works
  2. 2 Antibiotics Pharmacokinetics and Efficacy Pharmacology 2 works
  3. 3 Antibiotic Use and Resistance Applied Microbiology and Biotechnology 1 works
  4. 4 Complex Systems and Decision Making Management Science and Operations Research 1 works
  5. 5 Reproductive tract infections research Microbiology 1 works
  6. 6 Antimicrobial Resistance in Staphylococcus Infectious Diseases 1 works
  7. 7 Pharmaceutical studies and practices Pediatrics, Perinatology and Child Health 0 works
  8. 8 Bacterial Infections and Vaccines Microbiology 0 works
  9. 9 Bacterial biofilms and quorum sensing Molecular Biology 0 works
  10. 10 Pharmaceutical and Antibiotic Environmental Impacts Pollution 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available90.3%not open9.7%

World: 40% of research is openly available.

with international co-authors28.7%domestic only71.3%

World: 18% is written across borders.

How has Innoviva (United States)'s research output changed?

Output in 2022-2025 was 6900% higher than in 2018-2021.

still counting20202025
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Burlingame

All research institutions in Burlingame

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Innoviva (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.